Drug Information Association Logo

DIA/EFPIA Information Day on ICH

Mar 28 2014 8:00AM - Mar 28 2014 5:30PM | NH Danube City Wagramer Strasse 21 1220 Vienna Austria

« Back to Listing


The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved to respond to the increasingly global face of drug development, so that the benefits of international harmonisation for better global health can be realised worldwide. ICH's mission is to achieve greater harmonisation to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner.

During the Information Day, an update will be given both on status of active topics, new topics and ICH reforms regarding transparency, membership, governance and future funding.

Who Should Attend 

Professionals in regulatory affairs, regulatory submissions, pharmacovigilance, toxicology and quality assurance / quality control from industry and drug regulatory authorities, who want to be updated on the future of ICH and the status of active ICH topics.

Learning Objectives 

At the conclusion of this Information Day, participants should be able to:

  • Share knowledge about revised ICH Procedures and MedDRA development
  • Understand the background for ICH reforms
  • Discuss the status of active electronic and pharmacovigilance topics
  • Discuss the status of evolving safety and quality topics

Special Offers 


All four individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already discounted fees for government or charitable non-profit/academia offerings. To take advantage of this offer, please make a copy of the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to diaeurope@diaeurope.org.


Printable Registration Form

Hotel & Travel 

The Information Day will take place at:

Hotel NH Danube City

Wagramer Strasse 21

1220 Vienna, Austria

Tel.: +43 1 260 200

Email: nhdanubecity@nh-hotels.com

Contact Information 

DIA Europe
Kuechengasse 16
4051 Basel

Tel.: +41 61 225 51 51
Fax: +41 61 225 51 52
Email: diaeurope@diaeurope.org

Program Committee 

Previous Next


Day 1 Friday, Mar 28, 2014

  • 8:00AM - 9:00AM

  • 9:00AM - 10:30AM


    Session Chair(s):

    • Sarah Adam
      ICH Manager
      ICH Secretariat, Switzerland

    In 2012, building on 20 years of successful collaboration towards achieving greater international harmonisation for pharmaceutical products registration, the six official ICH parties have agreed on new principles of governance which better define the role of the regulator and industry parties within ICH, and also confirmed their commitment to strengthen ICH's global outreach. In June 2013, these new principles were integrated into the ICH Procedures document and applied to the ICH harmonisation process. At the same time, the Steering Committee agreed measures aimed at further increased transparency such as the publication on the ICH public website of: the entire ICH Procedures document, the working plans for each ongoing technical topic and the decisions taken at the SC meetings. This session aims to present the main changes in the revised ICH Procedures and also to provide you an overview of recent progress made towards ICH increased transparency. Information will also be given on recent development and governance of MedDRA.


    • Revised ICH Procedures to clarify Roles of Regulators / Industry
      Sarah Adam
      ICH Manager
      ICH Secretariat, Switzerland
    • Increased Transparency of ICH Activities
      Cornelia Meyer
      ICH Coordinator
      ICH Secretariat, Switzerland
    • MedDRA Governance and Development
      Claudia M. Lehmann
      Head Global Pharmacovigilance Operations
      Boehringer Ingelheim Pharma GmbH & Co KG, Germany
  • 10:30AM - 11:00AM

  • 11:00AM - 12:30PM

    Session 2: FUTURE OF ICH

    Session Chair(s):

    • Lenita Lindstrom-Gommers
      EU Member ICH Steering Committee, Senior Policy Officer
      European Commission , Belgium

    The session will give the background to initiatives from the EU to reform ICH and from EFPIA to develop new ICH topics. An update on what has been agreed so far and information on ongoing discussions on the future of ICH will be also given.


    • New ICH Topics
      Pär Tellner, MSc
      EFPIA ICH Coordinator, Director Regulatory Affairs
      EFPIA, Belgium
    • ICH Reforms, Discussions regarding Membership and Governance
      Lenita Lindstrom-Gommers
      EU Member ICH Steering Committee, Senior Policy Officer
      European Commission , Belgium
    • Principles for Funding of ICH in the Future
      Pär Tellner, MSc
      EFPIA ICH Coordinator, Director Regulatory Affairs
      EFPIA, Belgium
  • 12:30PM - 2:00PM

  • 2:00PM - 3:30PM


    Session Chair(s):

    • Joerg Schnitzler, PharmD, MSc, RPh
      Head of Global Regulatory Operations
      Boehringer Ingelheim Pharma GmbH & Co KG, Germany

    Growing needs for efficient handling of regulatory information require innovative electronic standards. Ten years after the successful introduction of eCTD v3.2.2 the M8 Expert Working Group (EWG) is currently working on the next major version of eCTD introducing v4.0 as a versatile exchange standard for electronic regulated product submissions. The M2 EWG provides in this context the framework for the development of new electronic ICH standards involving Standards Developing Organisations (SDOs). In parallel M2 currently evaluates, under its original mandate, future document standards for regulatory information addressing requirements for more structured information. Latest Pharmacovigilance activities include the preparation of a Q&A regarding the implementation and technical maintenance of the “Periodic Benefit / Risk Evaluation Report”, which the E2C(R2) Implementation Working Group (IWG) worked on after successfully reaching Step 4 in May 2013.


    • M2 Electronic Standards for the Transfer of Regulatory Information
      Stan A van Belkum, MSc
      Acting Director
      Medicines Evaluation Board, Netherlands
    • M8 The Electronic Common Technical Document
      Joerg Schnitzler, PharmD, MSc, RPh
      Head of Global Regulatory Operations
      Boehringer Ingelheim Pharma GmbH & Co KG, Germany
    • E2C (R2) Periodic Benefit / Risk Evaluation Report
      Valerie E. Simmons, MD, FFPM
      EU QPPV, Executive, Global Patient Safety
      Eli Lilly and Company Ltd, United Kingdom
  • 3:30PM - 4:00PM

  • 4:00PM - 5:30PM


    Session Chair(s):

    • Steven Spanhaak, MSc
      Scientific Director
      Janssen Research & Development, Belgium

    This session aims to provide information regarding a number of (evolving) ICH Safety and Quality guidelines. The presented spectrum ranges from more specific Safety (ICH S10, photosafety) and Quality (ICH Q7, GMP) topics to a clear area of overlap between Safety and Quality: impurity management (ICH Q3D, elemental impurities and ICH M7, DNA reactive impurities). Especially in the area of impurity management the last decade has provided a series of guidance documents to industry ranging from mutagenic impurities to metal catalysts. Although it is obvious that the common goal is to guarantee patient safety and quality of the products, the ever increasing challenge for industry and regulators is to strike a balance between perceived risks, (technical) capabilities and various guidelines.


    • S10 Photosafety Evaluation
      Ulla Waendel Limminga
      Scientific Director
      Medical Products Agency, Sweden
    • M7 Assessment and Control of DNA Reactive Impurities in Pharmaceuticals
      Steven Spanhaak, MSc
      Scientific Director
      Janssen Research & Development, Belgium
    • Q3D Elemental Impurities
      Michael J. James, PhD, MSc
      Director of CMC Regulatory Advocacy and Intelligence
      GlaxoSmithKline R&D, United Kingdom
    • Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
      Stephan Karl Roenninger, DrSc
      Director External Affairs Europe, International Quality
      Amgen (Europe) GmbH, Switzerland

Registration Fees 


Charitable Nonprofit/Academia Member
Member Government
Member Standard


Charitable Nonprofit/Academia Nonmember
NonMember Government
NonMember Standard
Register Online
« Back to Listing Back To Top